WP
OLMA icon

Woodline Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Woodline Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Buy
1,482,030
+100
+0% +$2.23K 0.08% 317
2025
Q4 		$37M Sell
1,481,930
-735,963
-33% -$13.1M 0.14% 183
2025
Q3 		$21.7M Sell
2,217,893
-1,288,000
-37% -$7.73M 0.1% 264
2025
Q2 		$14.9M Buy
3,505,893
+2,027,986
+137% +$9.04M 0.08% 349
2025
Q1 		$5.56M Buy
1,477,907
+120,428
+9% +$606K 0.04% 481
2024
Q4 		$7.91M Buy
1,357,479
+3,293
+0.2% +$32.9K 0.05% 397
2024
Q3 		$16.2M Buy
1,354,186
+501,632
+59% +$6.41M 0.14% 216
2024
Q2 		$9.22M Buy
852,554
+102,275
+14% +$1.11M 0.09% 258
2024
Q1 		$8.49M Hold
750,279
– – 0.08% 294
2023
Q4 		$10.5M Buy
750,279
+32,947
+5% +$443K 0.11% 224
2023
Q3 		$8.86M Buy
717,332
+129,280
+22% +$1.32M 0.1% 238
2023
Q2 		$5.31M Buy
+588,052
New +$3.55M 0.06% 279

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Woodline Partners's OLMA Position: Q1 2026 in Review

Woodline Partners increased its Olema Pharmaceuticals (OLMA) stake by 0.01% in Q1 2026, buying an estimated $2.23K and bringing the position to 1,482,030 shares worth $22.1M. The position accounts for 0.08% of the portfolio, ranked #317.

Woodline Partners first reported a position in OLMA in Q2 2023 and has held it in 12 quarters since. The position peaked at $37M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Woodline Partners held 1,482,030 shares of Olema Pharmaceuticals worth $22.1M as of Q1 2026.
  • Woodline Partners bought 100 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.23K.
  • Olema Pharmaceuticals made up 0.08% of Woodline Partners's portfolio in Q1 2026, its #317 holding.
  • Woodline Partners first reported a position in Olema Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Woodline Partners's Olema Pharmaceuticals position peaked at $37M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.